Bruker (NASDAQ:BRKR) Lowered to “Peer Perform” at Wolfe Research

Wolfe Research downgraded shares of Bruker (NASDAQ:BRKR) from an outperform rating to a peer perform rating in a research note released on Monday morning, MarketBeat reports.

Other equities analysts also recently issued research reports about the stock. TD Cowen decreased their price objective on shares of Bruker from $74.00 to $72.00 and set a hold rating for the company in a report on Wednesday, August 7th. The Goldman Sachs Group decreased their price objective on shares of Bruker from $72.00 to $60.00 and set a sell rating for the company in a report on Tuesday, July 9th. Jefferies Financial Group started coverage on shares of Bruker in a report on Monday, June 3rd. They issued a buy rating and a $85.00 price objective for the company. Wells Fargo & Company started coverage on shares of Bruker in a report on Tuesday, August 27th. They issued an overweight rating and a $78.00 price objective for the company. Finally, Citigroup decreased their price objective on shares of Bruker from $95.00 to $80.00 and set a buy rating for the company in a report on Wednesday, July 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bruker presently has an average rating of Hold and a consensus target price of $81.40.

Bruker Stock Down 2.5 %

Shares of NASDAQ:BRKR opened at $65.80 on Monday. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18. The company has a fifty day simple moving average of $65.36 and a 200 day simple moving average of $71.45. The firm has a market cap of $9.56 billion, a PE ratio of 23.80, a price-to-earnings-growth ratio of 2.43 and a beta of 1.18. Bruker has a 12-month low of $53.79 and a 12-month high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.52. The business had revenue of $800.70 million during the quarter, compared to analyst estimates of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The business’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.50 earnings per share. On average, equities research analysts anticipate that Bruker will post 2.61 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend was Friday, August 30th. Bruker’s dividend payout ratio (DPR) is 7.27%.

Hedge Funds Weigh In On Bruker

A number of institutional investors and hedge funds have recently bought and sold shares of BRKR. First Horizon Advisors Inc. grew its position in Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after buying an additional 218 shares in the last quarter. Rise Advisors LLC bought a new position in Bruker in the 1st quarter valued at about $27,000. Neo Ivy Capital Management bought a new position in Bruker in the 4th quarter valued at about $30,000. Covestor Ltd grew its position in Bruker by 139.1% in the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares in the last quarter. Finally, Gordian Capital Singapore Pte Ltd bought a new position in Bruker in the 2nd quarter valued at about $52,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.